Dayspring Pharma’s CG2001 Hits Phase II Goals in Male Pattern Hair Loss

Dayspring Pharma’s CG2001 Hits Phase II Goals in Male Pattern Hair Loss

By, Admin 22 April 2026

Hair loss treatments rarely deliver both speed and strength. This one might be getting closer.

Dayspring Pharma has reported positive Phase II results for CG2001 foam in men with:

  • Androgenetic Alopecia (AGA)

And the headline is simple: Primary endpoint met—with statistically significant and clinically meaningful outcomes.

Trial Snapshot: Designed for Signal, Not Noise

This wasn’t a loose exploratory study.

  • 110 male patients (China)
  • Multicenter, randomized, double-blind, placebo-controlled
  • 30-week duration
  • Led by Peking University People's Hospital

The goal:

  • Measure efficacy
  • Identify the optimal dose for Phase III

The Results: Combination Therapy Outperforms

All treatment arms beat placebo—but one stood out.

Best-Performing Regimen

  • 5% minoxidil + 0.075% finasteride (twice daily)

What it delivered:

  • ~50% higher efficacy vs existing Chinese minoxidil foam data
  • Faster onset, with strong results visible by Week 12
  • Continued improvement through Week 24

This is key. Most hair loss treatments take months to show modest gains. Here, the curve shifts earlier—and higher.

Why This Works: A Smarter Combination?

CG2001 isn’t reinventing the wheel. It’s optimizing it. It combines:

  • Minoxidil → stimulates hair growth
  • Finasteride → reduces DHT (root cause of hair loss)

But the innovation is in delivery:

  • Foam formulation
  • Optimized dose ratio
  • Enhanced follicular targeting
  • Reduced systemic exposure (a major concern with oral finasteride)

Translation: More drug where it’s needed. Less where it’s not.

Safety Profile: Clean and Predictable

No surprises—and that’s a good thing.

  • All adverse events were mild
  • Most common:
    • Itching (pruritus)
    • Scaliness
  • Resolved without intervention
  • Minimal systemic exposure observed

For a finasteride-containing therapy, this is critical.

What This Means for the Market?

AGA is crowded—but still flawed. Current options:

  • Work slowly
  • Deliver inconsistent results
  • Raise compliance issues (especially oral therapies)

CG2001 is aiming to fix three things:

  • Speed of results
  • Strength of efficacy
  • Safety via localized delivery

If Phase III confirms this, it becomes more than “another combo.”

What’s Next: Phase III Push?

Dayspring Pharma is moving forward with:

  • Phase III clinical development
  • Further optimization of:
    • Dosing
    • Real-world usability
    • Scalable manufacturing

The goal is clear: bring a faster, stronger, safer topical option to market.

Reality Check

Before calling it a breakthrough:

  • Data is Phase II (not definitive)
  • Population limited to Chinese male patients
  • Cross-trial comparisons (the 50% claim) can be misleading

The real test: Does this outperform existing standards in a large, diverse Phase III trial?

Final Take

CG2001 gets the fundamentals right:

  • Proven mechanisms
  • Improved delivery
  • Strong early data

That combination wins more often than not. Now it needs to prove it at scale.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!